PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents yoy growth below half of RVPH's 534.29%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of RVPH's 534.29%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of RVPH's 448.88%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of RVPH's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of RVPH's 448.73%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Less than half of RVPH's -23.99%. David Dodd sees a more disciplined AP approach or lower volume.
2.29%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
-2.29%
Less than half of RVPH's 27.69%. David Dodd sees fewer expansions in other current obligations.
-6.99%
Less than half of RVPH's 5.57%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Above 1.5x RVPH's -18.18%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Above 1.5x RVPH's -5.96%. Michael Burry sees a potential leverage warning sign.
10.53%
Less than half of RVPH's 44.96%. David Dodd sees fewer share issuances vs. competitor.
-2.12%
0.75-0.9x RVPH's -2.71%. Bill Ackman questions if competitor reinvests profits more robustly.
-7.96%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half RVPH's 664.34%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half RVPH's 448.73%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
-13.63%
Less than half of RVPH's -534.29%. David Dodd sees better deleveraging or stronger cash buildup than competitor.